Company Overview and News
TORONTO, July 16, 2018 (GLOBE NEWSWIRE) -- Sage Gold Inc. (“Sage Gold” or the “Company”) (TSX-V:SGX) reports that an application was issued on July 10, 2018 in the Ontario Superior Court of Justice against the Company. The applicant, CRH Funding II Pte. Ltd. (“CRH”), is seeking a court order appointing a receiver over the assets of Sage Gold, alleging that Sage Gold has failed to fulfill its gold delivery obligations to CRH.
TORONTO, June 28, 2018 (GLOBE NEWSWIRE) -- Sage Gold Inc. (“Sage Gold” or the “Company”) (TSX-V:SGX) has received a Notice of Intention to Enforce Security under section 244 of the Bankruptcy and Insolvency Act from Cartesian Royalty Holdings (“CRH”) on behalf of CRH Funding II Pte. Ltd., in respect of amounts owing under the Gold Payment Agreement (“GPA”) dated November 17, 2016. The Company is taking the notification seriously and is reviewing and considering its alternatives.
Sage Gold Inc. (“Sage Gold” or the “Company”) (TSX-V:SGX) is pleased to announce that it has completed the initial tranche of a treasury offering (the “Offering”) of units of the Company (the “Units”) at the price of $0.055 per Unit. Each Unit consists of one common share of the Company (a “Common Share”) plus one (1) Common Share purchase warrant (a “Warrant”). Each Warrant entitles its holder to purchase one Common Share at an exercise price of $0.
TORONTO, May 11, 2018 (GLOBE NEWSWIRE) -- Sage Gold Inc. (“Sage Gold” or the “Company”) (TSX-V:SGX) is providing a bi-weekly update on the status of the Management Cease Trade Order (“MCTO”) and an update of its ongoing mining activities at its Clavos gold mine in Timmins, Ontario.
TORONTO, April 27, 2018 (GLOBE NEWSWIRE) -- Sage Gold Inc. (“Sage Gold” or the “Company”) (TSX-V:SGX) is pleased to provide an update regarding its ongoing mining activities at the Clavos mine. The Company is now extracting mineralized material from 175E on the Footwall (FW) and Hanging wall (HW) drives after having completed development east of the existing level.
SGGDF SGX STADF
TORONTO, April 27, 2018 (GLOBE NEWSWIRE) -- Sage Gold Inc. (“Sage Gold” or the “Company”) (TSX-V:SGX) announced today that it expects that its audited financial statements, CEO and CFO certifications, and management discussion and analysis (the “Annual Filings”) for the year ended December 31, 2017 will not be released as scheduled on April 30, 2018. The Company currently anticipates being able to file the Annual Filings on or before May 23, 2018.
TORONTO, April 19, 2018 (GLOBE NEWSWIRE) -- Sage Gold Inc. (“Sage Gold” or the “Company”) (TSX-V:SGX) is pleased to announce that the Company has completed its latest bulk sample mill run. The custom mill processed 6,252 dry tonnes of mineralized material yielding approximately 513 ounces of gold.
SGGDF SGX STADF
TORONTO, March 28, 2018 (GLOBE NEWSWIRE) -- Sage Gold Inc. (“Sage Gold” or the “Company”) (TSX-V:SGX) is pleased to announce that the Company completed its latest bulk sample mill run on March 15, 2018 and the doré is now being refined. The custom mill processed 3,976 dry tonnes of mineralized material yielding approximately 312 ounces. The next mill run is expected to commence within the next two weeks.
SGGDF SGX STADF
2018-07-17 - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
2018-07-17 - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
as of ET